Thermo Fisher → PPD
Thermo Fisher expanded its clinical research services exposure in a resilient healthcare end market with a premium close to the fair range.
Fair value
Deal value
$17.4B
Announced
Apr. 15, 2021
Buyer type
Strategic
Consideration
Cash
Why ImpliedAI flags this deal
The preview model treats the deal as strategically sound with limited premium stretch due to strong end-market durability.
LabCorp / Covance
Selected precedent for strategic fit and premium context
ICON / PRA Health
Selected precedent for strategic fit and premium context
Danaher / GE Biopharma
Selected precedent for strategic fit and premium context
Research preview note: this page uses illustrative model outputs to demonstrate the product workflow. It is not investment advice and should not be treated as a final valuation opinion.